DrugPatentWatch Database Preview

Details for Patent: 10,137,167

« Back to Dashboard

Which drugs does patent 10,137,167 protect, and when does it expire?

Patent 10,137,167 protects NOCDURNA and is included in one NDA.

This patent has ninety-two patent family members in eighteen countries.

Summary for Patent: 10,137,167

Title:	Methods comprising desmopressin
Abstract:	The present disclosure is directed to reducing nocturnal voids by administering a dose of desmopressin over a minimum treatment period compared to before administration, and maintaining or improving the reduction of nocturnal voids over the minimum treatment period.
Inventor(s):	Klein; Bjarke Mirner (Frederiksberg, DK), Norgaard; Jens Peter (Frederiksberg, DK)
Assignee:	Ferring B.V. (Hoofddorp, NL)
Application Number:	14/143,866
Patent Claim Types: see list of patent claims	Use; Dosage form;

Drugs Protected by US Patent 10,137,167

Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	TE	Type	RLD	RS	Patent No.	Patent Expiration	Product	Substance	Delist Req.	Patented / Exclusive Use	Submissiondate
Ferring Pharms Inc	NOCDURNA	desmopressin acetate	TABLET;SUBLINGUAL	022517-002	Jun 21, 2018		RX	Yes	Yes						TREATMENT OF NOCTURIA DUE TO NOCTURNAL POLYURIA IN ADULTS, COMPRISING MONITORING A PATIENT'S SERUM SODIUM CONCENTRATION

International Family Members for US Patent 10,137,167

Country	Patent Number	Estimated Expiration	Supplementary Protection Certificate	SPC Country	SPC Expiration
Canada	2724653
Canada	2793502
China	102821776
China	106924716
China	107252474